P4 Diagnostix has teamed with Pierian, a company that provides an analysis platform, to launch somatic testing for patients with prostate cancer.
The partnership will further develop P4 Diagnostix’s urology testing services to include somatic testing by integrating the Illumina TruSight Oncology 500 cancer panel, according to a Sept. 28 news release from P4 Diagnostix.
Somatic testing will be incorporated with UroSeq, P4 Diagnostix’s current germline testing product.
The testing will launch at P4 Diagnostix’s laboratory in Indianapolis, the release said.